Get the latest news, insights, and market updates on AMLX (Amylyx Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
BofA Securities Lifts Amylyx Pharmaceuticals Inc. (AMLX) Price Target Amid Bolstered Balance Sheet
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 3, Bank of America Securities raised the stock’s price target to $16 from $14 while maintaining a ‘Buy’ rating. The price target hike comes on the heels of Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) raising $175 million on […] Oct 26, 2025 - $AMLX
Amylyx Pharmaceuticals (AMLX): Assessing Valuation After a Dramatic 260% Share Price Surge
Amylyx Pharmaceuticals (AMLX) shares have shown some movement over the past month, with the stock recently closing at $14.17. Investors may be watching closely to gauge how current trends could shape the company’s outlook. See our latest analysis for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals’ share price has soared more than 260% year-to-date, and the 90-day share price return also stands out at 77%, signaling strong momentum. However, the one-year total shareholder return of 167%... Oct 26, 2025 - $AMLX
Is AMLX Stock a Solid Choice Right Now?
Amylyx has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. Oct 16, 2025 - $AMLX
Will Amylyx Pharmaceuticals’ (AMLX) $175 Million Capital Raise Reshape Its Pipeline Ambitions?
Amylyx Pharmaceuticals, Inc. recently completed a follow-on equity offering, raising US$175 million by issuing 17,500,000 shares of common stock at US$10 per share, with a US$0.60 discount per share. This substantial capital raise could reinforce Amylyx Pharmaceuticals' ability to advance its product pipeline and support ongoing research initiatives. Next, we’ll explore how the influx of fresh capital from this offering shapes Amylyx Pharmaceuticals’ investment narrative and future... Sep 13, 2025 - $AMLX
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
CAMBRIDGE, Mass., September 10, 2025--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares of common stock are being offered by Amylyx. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price per share, l Sep 10, 2025 - $AMLX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple